Skip to Main Content
Try STAT+ TODAY
Trending:
Coronavirus
Health
Biotech
First Opinion

STAT+ Latest

Columns: Adam’s TakePharmalot

Topics: BiotechPharmaPolicyHealth TechBusiness

Features: STAT+ Conversations CRISPR TrackrDrug Pricing Policy Cheat SheetWebinars

Events: See upcoming events

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Sarepta halts a Duchenne clinical trial over safety; Why the CVS Health whistleblower lawsuit comes at a pivotal moment

By Ed Silverman

Sarepta - Cambridge -AP
Biotech

FDA halts study of Sarepta treatment for Duchenne muscular dystrophy due to safety concern

By Adam Feuerstein

CVS Pharmacy
Pharmalot

A CVS whistleblower lawsuit comes at a pivotal moment for the FTC’s probe of pharma and PBMs

By Ed Silverman

Adam's take main illustration
Adam's Take

A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser

By Adam Feuerstein

Pharmalot

Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK, Novartis pledge funds for diseases that mostly affect the poor

By Ed Silverman

uniQure
Biotech

Uniqure’s Huntington’s gene therapy lowers key protein in small trial

By Matthew Herper

Food And Drug Administration Headquarters 2020 fda hearing
Politics

Despite fanfare, the FDA’s step toward lowering nicotine levels in cigarettes is a very early one

By Nicholas Florko

Biotech

With cryptocurrency and NFTs, ‘decentralized science’ seeks to upend drug industry financing

By Allison DeAngelis

Senator Jeanne Shaheen in a red blazer speaking at a senate hearing.
Politics

New Senate proposal to lower insulin prices would let drugmakers lock in their current profits

By Rachel Cohrs

Politics

Congress is closer than ever to formally authorizing ARPA-H. But the details aren’t as final as they seem

By Lev Facher

pregnancy smartwatch
Health Tech

Wearables are collecting a flood of data. An ambitious new study of pregnancy aims to prove that’s valuable for health

By Mario Aguilar

Investing in health
Pharmalot

Industry-funded studies on cost-effectiveness often favor pricier drugs, study finds

By Ed Silverman

Pharmalot

Pharmalittle: U.K. inks $1.2 billion deal with Moderna for vaccine center; Top Biocon exec arrested in bribery scandal

By Ed Silverman

Health Tech

The pitfalls of pandemic apps, Epic’s data network, & Medicare’s race data problem

By Casey Ross and Katie Palmer

Biotech

Startup will target cystic fibrosis with a new twist on gene therapy

By Ryan Cross — The Boston Globe

Politics

Biden picks former DARPA director Prabhakar as next science adviser

By Lev Facher

Patent folder IP nationalism
Pharmalot

Senate lawmakers introduce a bill to help the FDA and the U.S. Patent Office coordinate

By Ed Silverman

Dialysis U.S.
Insurance

Supreme Court rules in favor of insurance plan that pushed kidney failure patient to Medicare

By Bob Herman

PTC Therapeutics
Biotech

PTC’s Duchenne muscular dystrophy drug achieves study goal, potentially confirming European approval

By Adam Feuerstein

Pharmalot

Pharmalittle: Medicare could have saved billions if it paid what Cuban charges; India’s drug controller accused of taking bribe

By Ed Silverman

Pharma

European researchers seek greater stake in drug development in bid to improve access

By Jessica Davis Plüss

Mark Cuban
Pharmalot

Medicare could have saved billions on drugs if it paid what Mark Cuban charges at his new pharmacy

By Ed Silverman

European Union flag
Pharmalot

European Commission investigates Vifor for ‘disparaging’ its only rival in iron deficiency market

By Ed Silverman

Health Tech

Smartphone apps promised to help combat the pandemic. How well did they work?

By Edward Chen

Pharmalot

Pharmalittle: Merck is eyeing Seagen to beef up its cancer drug portfolio; Lawmakers want GAO to probe PBMs

By Ed Silverman

Drug Pricing

Lawmakers ask GAO to probe pharmacy benefit managers over their role in drug pricing

By Ed Silverman

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

a photo of the federal trade comission building
Hospitals

HCA, Steward abandon hospital deal in another win for FTC

By Bob Herman